UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 123.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,505 shares of the company's stock after purchasing an additional 52,813 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.18% of Stoke Therapeutics worth $1,053,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics in the 4th quarter worth about $113,000. Tower Research Capital LLC TRC increased its holdings in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after acquiring an additional 4,918 shares during the last quarter. Invesco Ltd. acquired a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $133,000. Finally, ProShare Advisors LLC bought a new stake in Stoke Therapeutics during the 4th quarter valued at approximately $139,000.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company's stock, valued at $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,748 shares of company stock worth $225,687 in the last 90 days. Insiders own 9.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. HC Wainwright dropped their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Chardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $23.20.

Stoke Therapeutics Stock Down 2.5%

NASDAQ STOK traded down $0.29 on Friday, hitting $11.53. The company's stock had a trading volume of 478,274 shares, compared to its average volume of 699,976. The firm has a market cap of $629.50 million, a PE ratio of -5.49 and a beta of 1.09. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.34. The company's 50-day moving average is $9.18 and its 200 day moving average is $9.66.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.